We recommend that you upgrade to the latest version of your browser.
The image shows a pathology section on a slide, digital pathology sections with stained features, histotyping and further code snippets on a screen

Institute for Cancer Genetics and Informatics

For more than two decades, the Institute for Cancer Genetics and Informatics has been driving innovation in cancer diagnostics and prognostication. At the heart of our research is artificial intelligence, powering advanced image analysis of cancer cells and tissues to uncover tumour heterogeneity and disease progression. We create and refine digital tools, many of them within the field of pathology - making visualisation and interpretation of complex cancer images more precise and accessible. Through strong national and international collaborations, we turn cutting-edge research into real progress for cancer care.

Our vision is to strengthen Oslo University Hospital by providing knowledge and expertise to empower clinical decision-making and improve patient care. We develop innovative methods for cancer treatment, with a strong focus on digital image analysis and prognostication, paving the way for more precise and personalized diagnostics and therapy.
 
We focus on new technologies, often referred to as artificial intelligence (AI), and continue establishing new knowledge in the laboratory and then taking it to the clinic. This strategy requires an interdisciplinary approach, and close integration between scientists, technologists and clinicians. 

The institute is led by Tarjei Sveinsgjerd Hveem.

Section for Interphase Genetics

The section is led by Hanne Askautrud and is heavily involved in the institute's research activities. Marna Lill Kjæreng leads the unit for laboratories.

Section for Applied Informatics

John Arne Nesheim leads the section that works on software development, project management, operation of data systems, digital image analysis, quality assurance, web development, and research dissemination. The section has extensive expertise in developing systems for deep learning via neural networks, also referred to as artificial intelligence.

The Section for cancer cytogenetics was up until January 2026 a part of the institute  but is now a part of the department of Pathology

User council

Purpose of the User Council

Our User Council brings the perspectives of people affected by cancer into all aspects of the Institute’s research activities. Since 2019, the User Council offers strategic and practical guidance to ensure the Institute's research priorities aligns with users’ needs and experiences.

Value of user involvement

We are confident that meaningful user involvement strengthens our research quality, relevance, and impact, and supports responsible and ethically robust research practice.

Organisations Represented in our User Council

The User Council at ICGI is composed of representatives from the following national cancer patient organisations in Norway:

  • NORILCO (Gastrointestinal cancer) 
  • PROFO (Prostate cancer) 
  • The Norwegian Association for Gynaecological Cancer 
  • The Norwegian Society for Lung Cancer 
  • Norwegian association for melanoma (“Melanomforeningen”)
  • Norwegian association for sarcoma (Sarkomer)
  • Blodkreftforeningen (Hematopoietic cancer) 

External links to the institute's websites and project pages

Contact

Postal address

Instituttet er lokalisert i Ullernchausséen 64 i Oslo Cancer Cluster innovasjonspark, Radiumhospitalet. Blå lamell, inngang 2A (6. og 7. etasje).

E-mail

hramstad@ous-hf.no

Management group at ICGI

Management at ICGI
Tarjei Hveem is the Institute Director
Projects at ICGI
The ICGI runs several concurrent projects dedicated to enhancing the diagnosis, prognosis, and treatment of cancer. We are currently updating this list of project descriptions, so please keep in mind the list is not yet complete.